APAC Issue 11 2018

18 APAC / Issue 11 2018 , WuXi Biologics (2269.HK ), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, today announced that construction has commenced on a Biologics Manufacturing Center of excellence (MFG8), in the city of Shijiazhuang, one hour train from Beijing. The new Biologics Center with 48,000L bioreactor capacity, one of the largest global facilities using disposable bioreactors will be built to meet cGMP standards of the United States, the European Union, and China. It will be the 8th drug substance manufacturing facility of WuXi Biologics which plans to have more than 220,000L manufacturing capacity by 2021. “We are pleased to break ground today and look forward to the operations of this new Biologics Center. This facility will enable WuXi Biologics to develop and manufacture biologics more cost effectively as well as to provide a robust supply chain network for our global partners, and ultimately to benefit patients worldwide,” said Dr. Chris Chen, Chief Executive Officer of WuXi Biologics. WuXi Biologics Commenced Construction of 48,000L Biologics Commercial Manufacturing Center in Shijiazhuang The newBiologics Centerwill be one of the largest innorthernChina.